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(CPEB2) in human mammary epithelial cells
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Abstract
Background: Over-expression of cyclooxygenase (COX)-2 promotes breast cancer progression by multiple
mechanisms, including induction of stem-like cells (SLC). Combined gene expression and microRNA microarray
analyses of empty vector vs COX-2- transfected COX-2 low MCF7 breast cancer cell line identified two COX-2upregulated microRNAs, miR-526b and miR-655, both found to be oncogenic and SLC-promoting. Cytoplasmic
Polyadenylation Element-Binding Protein 2 (CPEB2) was the single common target of both microRNAs, the
functions of which remain controversial. CPEB2 has multiple isoforms (A-F), and paradoxically, a high B/A ratio was
reported to impart anoikis-resistance and metastatic phenotype in triple- negative breast cancer cells. We tested
whether CPEB2 is a tumor suppressor in mammary epithelial cells.
Methods: We knocked-out CPEB2 in the non-tumorigenic mammary epithelial cell line MCF10A by CRISPR/Cas9-double
nickase approach, and knocked-down CPEB2 with siRNAs in the poorly malignant MCF7 cell line, both lines being high
CPEB2-expressing. The resultant phenotypes for oncogenity were tested in vitro for both lines and in vivo for CPEB2KO cells.
Finally, CPEB2 expression was compared between human breast cancer and non-tumor breast tissues.
Results: CPEB2 (isoform A) expression was inversely correlated with COX-2 or the above microRNAs in COX-2-divergent
breast cancer cell lines. CPEB2KO MCF10A cells exhibited oncogenic properties including increased proliferation, migration,
invasion, EMT (decreased E-Cadherin, increased Vimentin, N-Cadherin, SNAI1, and ZEB1) and SLC phenotype (increased
tumorsphere formation and SLC marker-expression). Tumor-suppressor p53 protein was shown to be a novel translationallyregulated target of CPEB2, validated with polysome profiling. CPEB2KO, but not wild-type cells produced lung colonies upon
intravenous injection and subcutaneous tumors and spontaneous lung metastases upon implantation at mammary sites in
NOD/SCID/IL2Rϒ-null mice, identified with HLA immunostaining. Similarly, siRNA-mediated CPEB2 knockdown in MCF7 cells
promoted oncogenic properties in vitro. Human breast cancer tissues (n = 105) revealed a lower mRNA expression for CPEB2
isoform A and also a lower A/B isoform ratio than in non-tumour breast tissues (n = 20), suggesting that CPEB2A accounts
for the tumor-suppressor functions of CPEB2.
Conclusions: CPEB2, presumably the isoform A, plays a key role in suppressing tumorigenesis in mammary epithelial cells
by repressing EMT, migration, invasion, proliferation and SLC phenotype, via multiple targets, including a newly-identified
translational target p53.
Keywords: CPEB2, Tumor suppressor, COX-2, EMT, EP4 receptor, Breast Cancer, Stem-like cells, MicroRNA-526b, MicroRNA655, p53, Polysome profiling
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Background
Upregulation of cyclooxygenase (COX)-2, an inflammationassociated enzyme, noted in half of the breast cancer patients
[1] promotes tumor progression and metastasis through multiple mechanisms, including increased cancer cell proliferation,
migration, invasion, epithelial-to-mesenchymal transition
(EMT), tumor-associated angiogenesis, lymphangiogenesis,
and induction of stem-like cells (SLCs) [2–6]. SLCs represent
a dynamic state regulated by the tumor micro-environment
[7] and resist chemo- and radiation therapies, causing tumor
recurrence [8, 9]. COX-2 mediated stimulation of various
oncogenic events in breast cancer, as listed above, is largely
due to the activation of the PGE receptor EP4 by the endogenous Prostaglandin (PG)E2 [10].
Combined gene and microRNA expression microarrays
with ectopic COX-2 overexpressing and Mock (empty
vector-transfected) MCF7 breast cancer cells [6] revealed
26 genes that are downregulated, along with two microRNAs, miR-526b [11] and miR-655 [12] that are upregulated by COX-2. MicroRNAs silence their gene targets
either by degrading the mRNAs or blocking their translation [13]. We found that both miRNAs - miR-526b and
miR-655 were oncogenic and SLC-promoting [11, 12].
The only COX-2 down-regulated gene targeted by both
microRNAs was identified as Cytoplasmic Polyadenylation
Element-Binding Protein 2 (CPEB2), the functions of
which in tumor biology remain controversial.
The CPEB family includes 4 members (CPEB1–4) which
regulate translation of their target mRNAs by binding to a
Cytoplasmic Polyadenylation Element (CPE) in the 3’untranslated region [14]. Polyadenylation in their target
mRNAs depends on both a CPE sequence (UUUUUAAU)
and a polyadenylation hexanucleotide signal (AAUAAA)
[15]. CPEB proteins can repress or activate translation of
target mRNAs by respectively shortening or elongating
the poly-A tail [16]. CPEB1 was shown to be a tumorsuppressor, depletion of which in mammary epithelial cells
led to Epithelial-Mesenchymal-Transition (EMT) and
metastatic phenotype [17]. It restrained proliferation of
glioblastoma cells by activating p27 mRNA reanslation
[18]. CPEB3 appeared to be a tumor-suppressor, targeted
by oncogenic miR-107 in hepatocellular carcinoma [19].
Furthermore, a high CPEB3 protein expression was associated with increased survival in renal cell carcinoma patients [20]. The roles of CPEB4 in tumors remain
conflicting. A tumor- suppressor role was demonstrated by
its being the target of an oncogenic miR-550A in hepatocellular carcinoma [21]. However, CPEB4 mediated translational activation of oncogenic mRNAs in pancreatic cancer
[22], and EMT induction, growth and metastasis in gastric
cancer cells [23] illustrate pro-oncogenic functions.
The role of CPEB2 in cancer remains paradoxical. A
tumor-suppressor role was suggested by CPEB2 binding to
HIF1α mRNA and suppressing its translation under
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normoxic conditions, but releasing it to allow translation
under hypoxic conditions [24]. This results from interaction
with the elongation factor eEF2 [25]. HIF1α is short-lived
under normoxic conditions, but stabilized under hypoxic
conditions to stimulate genes promoting angiogenesis, EMT,
migration, SLC functions, metastasis and therapeutic resistance [26]. Binding of CPEB2 to the mesenchymal transcription factor TWIST1 down-regulated its translation [27],
suggesting an EMT-suppressor function. A tumorsuppressor role of CPEB2 was further suggested by its
down-regulation by microRNA-885-5p, a mediator of EMT,
tumorigenesis and metastasis in colorectal cancer [28].
The roles of CPEB2 in breast cancer appear to be
complex, depending on the expression of different
CPEB2 isoforms. CPEB2 has six isoforms (A-F). By
selecting cells for anoikis-resistance in vitro from triplenegative breast cancer (TNBC) cell lines, Johnson et al.
[29] reported that an alternative splicing of CPEB2, leading to a high isoform B:A ratio mediated anoikisresistance and metastatic phenotype. They suggested
that isoform A which excludes exon 4 is a tumor- suppressor, whereas isoform B that includes exon 4, is a
tumor-promoter. This suggestion was validated by next
generation sequencing and isoform-specific downregulation of CPEB2A and B in TNBC lines [30]. They
concluded that CPEB2B plays an antagonistic role
against CPEB2A by alleviating the translational inhibition of HIF-1α and Twist 1 imparted by CPEB2A.
We adopted a different approach to examine the functions of CPEB2 in breast epithelial cell lines, by depleting the entire CPEB2 gene and observing the resultant
phenotypic changes: (a) CPEB2 was knocked out using a
double nickase CRISPR plasmid in an immortalized
non-tumorigenic human mammary epithelial cell line
MCF10A, reported to be a reliable model for normal
mammary epithelium [31]; (b) CPEB2 was knocked
down with siRNAs in the MCF7 cell line, a mammary
carcinoma of low malignancy [6]. CPEB2KO MCF10A
cells exhibited an oncogenic phenotype in vitro, as indicated by increased proliferation, migration, invasion,
EMT, stimulation of SLC and a downregulation of p53
tumor suppressor protein owing to a decreased translation of p53 mRNA. They exhibited lung colonization after
intravenous injection and subcutaneous tumorigenicity
upon inoculation at the mammary sites in NOD/SCID/
IL2Rγ null mice. SiRNA-mediated CPEB2 knockdown in
MCF7 breast cancer cells also resulted in enhanced oncogenic properties tested in vitro. These results confirm
CPEB2 as a tumor-suppressor in breast epithelial and
poorly malignant breast cancer cells likely resulting from
the CPEB2A isoform prevalence in these cells. This contention was supported by a higher CPEB2A isoform expression and A: B isoform ratio in non-tumorous human
breast tissues than in cancerous breast tissues.
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Materials and methods
Cell culture

The immortalized non-tumorigenic mammary epithelial cell line MCF10A (ATCC, at 4–6 passages) was
cultured in DMEM (Gibco, Thermofisher, CA) supplemented with 5% horse serum (Invitrogen, Thermofisher, CA), 20 ng/ml EGF, 0.5 mg/ml hydrocortisone
(Sigma, Oakville, ON, CA), 100 ng/ml cholera toxin
(Sigma), 10 μg/ml insulin (Sigma), and 1% penicillin/
streptomycin (Invitrogen) [31]. MCF7 cells (ATCC,
Manassas, VA, USA, at 4–6 passages) were grown in
EMEM supplemented with 10% FBS, 100 μg/mL of
penicillin/streptomycin (Gibco) and 10 μg/mL of insulin (Sigma).

CRISPR knockout of CPEB2 and SiRNA mediated CPEB2
knockdown

Total CPEB2 was knocked out in MCF10A cells with a
CRISPR double nickase plasmid (Santa Cruz, Dallas, TX,
USA) targeting exon 1 of the gene, that combines a Cas9
nickase mutant with pairs of guide RNAs to introduce
targeted double-strand breaks, ensuring a high knockout
specificity [32]. Cells transfected with Amaxa Cell Line
Nucleofector Kit IV (Lonza, Allendale, NJ, USA) were
subjected to 72 h of puromycin selection and expanded.
MCF7 cells were transfected with 1 μM of either CPEB2
siRNA (a pool of siRNAs that gave the best results) or
Universal Scrambled Control siRNA (OriGene, Rockville, MD, USA). After 24 h media was changed and experiments conducted at 48 h. CPEB2 downregulation in
KO and KD cells was validated with qRT-PCR.

Protein extraction and Western blot

Proteins extracted from cell lysates were subjected to
western immunoblots [6], using primary antibodies at
the following dilutions: CPEB2 (Origene cat #
TA344026, rabbit polyclonal, 1:1000; lacking isoformspecificity), E-Cadherin (Cell Signalling, Danvers, Mass,
USA, rabbit monoclonal, 1:1000), Vimentin (Cell Signalling, rabbit monoclonal, 1:1000), β-actin (Santa Cruz,
mouse monoclonal, 1:4000 or Cell Signalling, rabbit
monoclonal, 1:1000), N-Cadherin (Santa Cruz, Rabbit
polyclonal, 1:400), p53 and p21 (both from Novus Biologicals, Centennial, Colorado, USA, mouse monoclonal,
1:200) and β-Catenin (Sigma, rabbit polyclonal, 1:4000).
After primary antibody incubation overnight, membranes were incubated for 1 h with appropriate secondary antibody at the following dilutions: Goat
Anti-Rabbit (1:10000, Li-COR, Lincoln, Nebraska,
USA) and Donkey Anti-Mouse (1:10000, Li-COR).
Membranes were scanned using the Odyssey Infrared
Imaging System (Li-COR).
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Immunofluorescence
Monolayers

Cells grown on glass coverslips were treated with various primary antibodies as reported [6]: E-Cadherin (Cell Signalling,
1:500), Vimentin (Cell Signalling, 1:500), and N-Cadherin
(Sigma, 1:500). The cells were then incubated with
fluorochrome-conjugated secondary antibodies (Biotum,
Cedarlane, Burlington, ON, CA) at the following dilutions:
Goat Anti-Rabbit 594 (1:500), Goat Anti-Rabbit 488 (1:500)
and Goat Anti-Mouse 488 (1:500). Vectashield anti-fade
mounting medium with DAPI (Vector-labs, Burlignton, ON,
CA) was used to mount the slides. Fluorescent images were
taken with Zeiss LSM 510 Meta Multiphoton Confocal
Microscope, and fluorescence intensities calculated with
ImageJ software. The raw integrated density was calculated
for each cell and normalized to the cell area. Data were presented as an average of all cells.
Tumorspheres (spheroids)

Fixation, permeabilization, and antibody staining for
tumorspheres (minimum 60 μm diameter) were conducted as reported [6]. Incidence of fluorescent cells (for
ALDH1, NANOG, and SOX-2) was computed among
total number of cells marked by DAPI.
Migration and invasion assays using Transwells

Semi-confluent MCF10A and MCF7 cells were serumstarved overnight and seeded on microporous membranes (8 μm pore diameter) coated without or with
Matrigel respectively for migration and invasion assays
using transwell inserts [6]. Bottom chambers included
5% horse serum to stimulate migration or invasion respectively for 24 and 48 h. The cells at the bottom of the
membranes were fixed with cold methanol, stained with
Eosin (cytoplasm) and Thiazine (nucleus), and mounted
onto glass chamber slides to count all cells. Assays were
done in triplicate.
Migration (wound-healing) assays using scratch method

Cells grown to semi-confluency were serum-starved
over-night. Proliferation inhibitor mitomycin C (1 ng/μl)
was added 2 h before the plate was scratched with a
microtip. Cells were then incubated in medium including 1% horse serum and mitomycin C for 72 h, replacing
media every 24 h. Migration, un-affected by proliferation
was measured as the distance covered per unit time.
Zymography

Cell-free conditioned media were collected at 24 h and
frozen at − 20 °C. 10% zymogram gels were made with
Gelatin A to measure gelatinolytic activity. Conditioned
medium mixed 1:1 with zymogram sample buffer, was
loaded and run at 110 V for 90 min. The gel was incubated in zymogram renaturation buffer for 1 h, then in
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zymogram developing buffer for 1 h, and finally overnight at 37 °C in fresh zymogram developing buffer (all
from BioRad, Mississauga, ON). Gels stained with Coomassie Blue were imaged using the BioRad XR+ Gel
documentation system.
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Animal experiments for tumorigenicity assays

MCF7 and MCF10A cells were grown as spheroids on
ultra-low attachment plates as reported [6]. In brief, cells
grown to 70–80% confluency were trypsinized and spun
down. They were then suspended in basal HuMEC media
(Gibco) with added B-27 supplement (Gibco), EGF (20
ng/mL, Invitrogen) and FGF (20 ng/mL, Invitrogen), taken
up by a 1 mL syringe and put through a 40 μm cell
strainer (Falcon) to collect a single cell suspension. The
cells were then counted and seeded at a density of 10
cells/well in an ultra-low attachment 96-well plate
(Thermo Fisher) to measure spheroid forming efficiency
(SFE), as well as 1 × 103 cells/well in an ultra-low attachment 6-well plate (Corning, NY, USA) for for RNA analysis and immunofluorescence. SFE was calculated at 4
days as the total number of spheroids (minimum 60 μm in
diameter) divided by total number of cells plated.

NOD/SCID/IL2Rγ-null (NSG) mice (deficient in T, B
and NK cells) were bred locally by Dr. David Hess (coauthor) and maintained according to the Canadian
Council of Animal Care guidelines with food and water
ad libitum at the Robarts Research Institute mouse barrier. The protocol was approved by the Animal Care and
Veterinary Services (ACVS) committee on animal use.
Six-week-old females were used as hosts for tumorigenicity assays by intravenous or subcutaneous routes using
5 × 105 CPEB2KO and WT MCF10A cells per mouse.
They were euthanized with CO2 at the appropriated time.
Tail vein injected mice (n = 6) were sacrificed at 8 weeks
to isolate lungs, spleen and liver to assess metastases. Cells
mixed 1:1 with Matrigel were injected S.C. into both right
and left inguinal mammary regions of 5 mice each for
CPEB2KO or parental cells (total = 10 sites each). After
12 weeks at sacrifice, one mammary fat pad was stored in
O.C.T. for frozen sectioning and the other in Bouin’s solution for paraffin embedding. Lungs, liver and spleen were
also harvested to assess spontaneous metastasis from
mammary sites. All lungs were inflated with PBS prior to
isolation. All mice were weighed once per week.

Polysome profiling

Tissue processing from mice

Polysome profiling was performed as reported [33]. WT
or CBEB2KO MCF10A cells were pre-treated with cycloheximide (CHX, 100 μg/mL) for 5 min at 37 °C. Cells were
washed twice with ice-cold PBS containing 100 μg/mL
CHX and lysed in hypotonic buffer (100 mM KCl, 50 mM
Tris–HCl pH 7.4, 1.5 mM MgCl2, 1 mM DTT, 1 mg/mL
heparin, 1.5% NP40, 100 μg/mL CHX, supplemented with
mini cOmplete™ Protease Inhibitor Cocktail tablet and
100 Unit RiboLock RNase inhibitor). The lysates were incubated on ice for 5 min and cleared by centrifugation at
12000 rpm for 5 min at 4 °C, prior to loading on 10–50%
sucrose gradients to isolate the sub-polysomal and polysomal fractions. Total RNA was isolated from each fraction
using Trizol reagent and converted to cDNA using SuperScript III First-Strand Synthesis System (Life Technologies, Burlington, ON). RT-PCR was performed for each
gene using a PCR thermocycler (Bio-Rad) and visualized
by agarose gel electrophoresis.

Lungs, liver and spleen were stored either in O.C.T for cryosectioning or Bouin’s solution/Neutral-Buffered Formalin for
fixation and paraffin embedding. Paraffin blocks were sectioned at 5 μm and stained with H&E. Frozen organs were
sectioned at 8 μm for lungs, liver and spleen, while mammary fat pads were sectioned at 10 μm. Sections were then
fixed in 10% formalin, permeablized in 0.1% Triton-X-100,
and blocked with M.O.M (mouse-on-mouse Ig, Vector labs,
Burlington, ON) prior to immuno-staining. Mouse antiHLA antibody (1:100, BD, Mississauga, ON), followed by
horse anti-mouse FITC (1:200, Vector Labs) was applied to
detect human cells. Sections were mounted with Vectashield
(Vector Labs), stained with DAPI and viewed under a fluorescent microscope. Micrometastases were arbitrarily scored
as single cells, clusters (2–8 cells) and colonies (> 8 cells) as
reported earlier [6] and averaged within 3 sections, 5 images
of 1600μm2 each per section.

Tumorsphere (spheroid) formation assay

Cell proliferation assays

WT or CPEB2KO MCF10A cells were incubated for 24 h in
complete media with or without EDU (negative control for
autofluorescence) using Click-iT EdU Alexa Fluor 488 Imaging kit (Invitrogen). EdU incorporation was measured in an
analytical flow cytometer. BrdU incorporation was measured
in WT, MOCK and CPEB2KD MCF7 cells using the Cell Proliferation ELISA, BrdU (colorimetric) Kit (Roche, Sigma) and
an Epoch Microplate Spectrophotometer at a wavelength of
370 nm with a reference wavelength of 492 nm.

Measurements of CPEB2 expression in human breast
cancer cell lines, breast cancer and non-tumor breast
tissues

Using the blast search, we found that primers used by
Johnson et al. [29] for CPEB2A covered all 6 isoforms,
whereas primers used for CPEB2B covered both isoforms B
and D. In our study we used probes with increased isoform
specificity: a Taqman probe for isoform A/E and another
probe for isoform B/D (Applied Biosystems, ThermoFisher)
to conduct qPCR in a panel of human breast cancer tissues
(n = 105) and non-tumor breast tissues (n = 20) obtained
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from the Ontario Tumor bank (OTB) maintained by the
Ontario Institute of Cancer Research (OICR) following ethics
approval by the OICR committee. This bank receives tumor
tissues from donors in Ontario hospitals following donor
consent. Taqman probes (Applied Biosystems) for GAPDH
and β-Actin were used as the internal loading control. Delta
Ct values were calculated by subtracting the average Ct
values (triplicate) from the control and analyzed as previously described [6].
The probe for isoform A/E was also utilized to compare CPEB2A expression in a panel of COX-2 disparate
human breast cancer cell lines MCF7, MCF7-COX2,
MDA-MB-231 and SKBR3. To conduct qPCR for CPEB2
in MCF7 cells we used a Taqman probe from Life Sciences, which is not isoform-specific. To conduct RTPCR for CPEB2 in MCF10A cells, we designed oligos to
cover all isoforms: Forward: ACACTCTTACCCTTACAGGTG; Reverse: CGCCCATAACTCCTTGCATT.

Statistical analysis

Statistical analyses were performed using Graphpad
Prism Software 5.0 (Graphpad Software Inc. 2007).
All parametric data were analyzed with one-way
ANOVA followed by Tukey-Kramer or Dunnett’s
post hoc comparisons. Spheroid and lung colony
numbers were analyzed both by parametric and nonparametric (Mann-Whitney test) methods, giving
similar results. Student’s t test was used to compare
two datasets. Statistically relevant differences between means were accepted at p < 0.05.

Results
CPEB2 is the single COX-2 down-regulated gene targeted
by miR-526b and miR-655

We found that miR-526b and miR-655 collectively targeted a total of 13 COX-2 -down-regulated genes, 12 of
which are tumor-suppressor-like. The remaining single
gene targeted by both microRNAs was identified as
CPEB2 (Additional file 4: Table S1).

CPEB2 expression levels in multiple breast cancer cell
lines

CPEB2 mRNA expression (of the A/E isoform) compared in multiple COX-2 divergent cell lines (Fig. 1a)
shows an approximately inverse relationship with COX-2
and the miR-526b and miR-655 expression levels. Similarly CPEB2 protein levels (measured in western blots
with an isoform-non-selective antibody, that produced a
single band of putative isoform A (approx. 60 kDa) were
higher in COX-2-low (MCF7, T47D) than in COX-2high (MDA-MB-231, HS578T) cells (Fig. 1b).
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Validation of CPEB2 down-regulation in CPEB2KO
MCF10A cells and CPEB2KD MCF7 cells

CPEBE2 mRNA and protein levels were very high in
MCF10A cells, in which we knocked-out CPEB2 (inclusive of all isoforms) using a double nickase CRISPR plasmid to ensure high specificity. A comparison of mRNA
and protein levels in WT and KO cells (Fig. 1c) demonstrated approximately 80% knock-out efficiency (Fig. 1d).
PCR data revealed a single band corresponding to isoform A, both in WT and CPEB2KO MCF10A cells confirming that MCF10A cells lack in the B isoform [29].
We also knocked down CPEB2 in the poorly malignant,
CPEB2A dominant breast cancer cell line MCF7, using a
pool of siRNAs. Scrambled siRNAs served as controls
(Mock cells). An efficient knock-down (approximately
75% relative to WT or Mock cells) was noted at the
mRNA level (agarose gel picture in Fig. 1e; quantification of Fig. 1e presented in Fig. 1f ).

CPEB2 downregulation in breast epithelial cells induces
EMT and promotes migration and invasion

Upon CPEB2 knock-out, the epithelial-like (polygonal
shaped) wild-type MCF10A cells (Fig. 2a) assumed a
mesenchymal-like (spindle-shaped) morphology (Fig. 2b). To
test an association of this morphological change with EMT,
we compared EMT markers in WT and CPEB2KO cells
using qRT-PCR and Western blots. mRNA expression for
the epithelial marker CDH1 (E-Cadherin, a transmembrane
protein) was suppressed, with a concomitant increase in
mesenchymal markers VIM (Vimentin, an intermediate filament) and two transcription factors SNAI1 and ZEB1 (Fig.
2c). Western blots revealed a near-complete depletion of ECadherin and increases in mesenchymal markers NCadherin and Vimentin proteins (Fig. 2d and e). Cellular immunofluorescence for the respective proteins corroborated
this phenotype of reduced E-Cadherin, increased NCadherin and Vimentin (Figs. 2g showing morphology, and
2F quantitation). Similarly, CPEB2KD MCF7 cells also displayed EMT phenotype, as illustrated by a significant downregulation of E-Cadherin and upregulation of Vimentin and
TWIST proteins relative to WT or Mock-transfected MCF7
cells, identified with immunofluorescence and Western blots
(Additional file 1: Figure S1).
EMT is a functional associate of cellular migratory and
invasive abilities due to changes in molecular expression
profiles. For example, loss of E-Cadherin emancipates
cells from contact inhibition [34, 35], whereas an increase in Vimentin mediates cytoskeletal reorganization
needed for motility [36]. To assess changes in migration
alone independent of proliferation, cells were serumstarved overnight and incubated with mitomycin C prior
to scratching (or wound-healing) assay. CPEB2KO cells
migrated at a significantly faster rate than wild-type cells
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Fig. 1 CPEB2A expression in various un-manipulated and manipulated cell lines. a COX-2, miR-655, miR-526b and CPEB2A were quantified in
different (COX-2 disparate) breast cancer cell lines, relative to MCF7 cells. Cell lines (MDA-MB-231 and MCF7-COX-2) with high COX-2 and miRNAs
expression showed low expression of CPEB2A (measured with an A/E probe). b Western blots for CPEB2 protein (about 60 kDa, presumably CPEB2
A, identified with an isoform nonselective antibody) revealed a similar trend, high expression of CPEB2 in poorly malignant, low COX-2 expressing
MCF7 and T47D cells, and low expression in high COX-2 expressing and metastatic MDA-MB-231 and Hs578T cells. c, d CPEB2 knockout (KO)
through a double nickase CRISPR plasmid in MCF10A cells resulted in downregulation of CPEB2 mRNA (shown with RT-PCR) and protein (shown
with Western blot). CPEB2 protein expression was knocked out with 80% efficiency. e, f. SiRNA-mediated knockdown of CPEB2 mRNA using a
pool of siRNAs in MCF7 cells shows 75% downregulation. Data presented as mean of 3 replicates ± SEM. (*) indicates p < 0.05, (**) p < 0.001,
(***) p < 0.0002

during 72 h (Fig. 3a and b). By 24 h, the migration was
10-fold faster.
Migration was also measured in transwells (chemokinesis
assay), in which serum-starved cells were allowed to migrate
through microporous membranes for 24 h into a medium
containing 5% Horse Serum. CPEB2KO cells migrated faster
than WT cells (Fig. 3c). Similarly, CPEB2KD MCF7 cells also
migrated faster than the Mock (scrambled siRNA-transfected)
or WT MCF7 cells (Additional file 2: Figure S2A).
Ability to invade basement membrane components is
an important prerequisite for metastasis. Invasion was
measured as above for 48 h, in which the microporous
membranes were coated with a basement membrane
analog Matrigel. CPEB2KO MCF10A cells exhibited a
higher invasive ability than WT cells (Fig. 3d). CPEB2KD

MCF7 cells also showed significantly higher invasiveness
than Mock or WT MCF7 cells (Additional file 2: Figure
S2B). Increased matrix-degrading ability of CPEB2KO
MCF10A cells was corroborated by gelatin zymography,
showing a 2.9 fold increase in gelatinase A (MMP-9) activity (Fig. 3h).

CPEB2KO promotes proliferation

Sustained proliferative ability is a hallmark of cancer cells
[37]. Flow cytometry for 5′- ethynyl-2′-deoxyuridine (EdU)
incorporation (measuring DNA synthesis) for 24 h revealed a
four-fold increase in CPEB2KO MCF10A cells compared to
WT cells (Fig. 3e and f) in 3 replicate preparations.
CPEB2KD MCF7cells, however, exhibited only a minor
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Fig. 2 Epithelial to mesenchymal transition in CPEB2KO cells. a Wildtype (WT) MCF10A cells exhibiting epithelial cell morphology. b CPEB2KO
cells exhibiting elongated, mesenchymal (Fibroblast-like) morphology (Magnification viewed at10x objective). c Quantitative RT-PCR for EMT
marker mRNAs in WT and CPEB2KO MCF10A cells. Epithelial marker E-Cadherin was significantly decreased (to 0.116 fold), with significant
increases in mesenchymal markers ZEB1 (4.06 fold), Vimentin (1.49 fold), and SNAI1 (4.38 fold) in CPEB2KO cells. d, e Induction of EMT in CPEB2KO
cells shown at the protein level. Representative Western blots (d) and quantification of Western Blots (e) for E-Cadherin, Vimentin and N-Cadherin
in wildtype and CPEB2KO cell lines showing significantly decreased E-Cadherin protein (to 0.078 fold), significantly increased Vimentin (to 2.75
fold) and N-Cadherin (to 6.93 fold) in CPEB2KO cells. f, g EMT visualized through immunofluorescence of markers. g. E-Cadherin (red), Vimentin
(green), and N-Cadherin (green); Nuclei (blue). Magnification Scale = 20 μm. f. Integrated fluorescence density quantified with ImageJ Software
and normalized to cell number, showing that E-Cadherin protein expression was significantly decreased (to 0.20 fold), with a significant increase
in Vimentin (to 3.50 fold) and N-Cadherin (to 1.80 fold) in CPEB2KO cells compared to WT cells. Data presented as mean of 3 replicates ± SEM. (*)
indicates p < 0.05, (**) p < 0.001

increase (p = 0.06) in proliferative ability compared to mock
cells (Additional file 2: Figure S2C).
P53 translation is repressed in CPEB2-KO cells

CPEB1 and CPEB2 were reported to co-regulate two
transcription factors HIF1α [24] and TWIST1 [27].
CPEB1 was also shown to be a translational regulator of
p53, a powerful tumor- suppressor. P53 mRNA contains
2 CPE domains in its 3′ UTR, which promote polyadenylation. In CPEB1 knock-down cells, p53 mRNA had
an abnormally short poly (A) tail reducing translational
efficiency and a marked decrease in p53 protein [38].
Hence using CPEB2KO MCF10A cells we examined

whether p53 is a candidate translational target of CPEB2.
qRT-PCR revealed no significant difference in p53
mRNA expression between CPEB2KO and WT cells
(Fig. 4a). However, p53 protein levels measured with
western blot, revealed ∼60% reduction (Fig. 4b and c),
suggesting that p53 is differentially regulated at the
translational level. We also examined expression of p21
protein, a downstream effector of p53, using western
blot and found a 66% reduction in the CPEB2KO cells
(Fig. 4d and g), indicating that the p53 pathway is negatively affected.
To interrogate whether p53 protein was translationally
regulated by CPEB2, we compared polysome profiling
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Fig. 3 Comparison of migration, invasion and proliferation in WT and MCF10A CPEB2KO cells. a Representative images of WT and CPEB2KO
MCF10A cells that were scratched and allowed to migrate in 1% Horse Serum, in the presence of mitomycin C to block proliferation. b Cell
migration rate was measured as (distance at 0 h – distance at 24 h or 48 h or 72 h). WT cells migrated in a rate of 3.57 μm/day, whereas CPEB2KO
cells migrated 35.82 μm/day. Scale = 100 μm. c Migration and (d) invasion of WT and CPEB2KO MCF10A cells in transwell chambers. Serum
starved cells were allowed to migrate/invade in the presence of 5% Horse Serum in the bottom chamber. Cells were treated with Mitomycin C to
block proliferation. The migration rate was 10.89 fold and invasion 3.43 fold in CPEB2KO cells relative to WT cells. e, f Proliferation (24 h EdU
uptake measured with flow cytometry for immune-fluorescence) showing about 4 fold increase in CPEB2KO cells relative to WT cells in a
representative assay. g Data presented as mean normalised % difference in proliferation between KO and WT cells (KO-WT)/WT. h Gelatinase A
(MMP9) activity in WT and CPEB2KO MCF10A cells measured with densitometry of zymograms, WT cells normalised to 1. Quantitative data
presented as mean of 3 ± SEM. (*) indicates p < 0.05, (**) p < 0.001, (***) p < 0.0005

between WT and CPEB2KO MCF10A cells. The profile
appeared almost identical indicating no significant
difference in global translation between the two cell
types (Fig. 4e). RT-PCR was performed to evaluate
the distribution of β-actin and p53 mRNAs across a
sucrose density gradient. While β-actin distributions
were similar in both cells, p53 mRNA was significantly shifted toward light polysomes in CPEB2KO
cells (Fig. 4f ). These results, combined with the findings of the absence of any change in p53 mRNA in
CPEB2KO cells, clearly reveal that CPEB2 knock-out
decreased the translation of p53 by shortening the
Poly A tail leading to decreased p53 protein.

CPEB2KO/KD stimulates SLC phenotype

CPEB2 being a common target of both SLC-promoting
miRNAs, we examined whether CPEB2 downregulation
in MCF10A and MCF7 cells stimulated SLC properties
using the spheroid (tumorsphere) formation assay which
measures the ability of single cells to self-renew in an
anchorage-independent manner when grown on ultralow attachment plates [6]. CPEB2KO MCF10A cells displayed significantly increased spheroid formation
(morphology shown in Fig. 5a) and spheroid forming efficiency (SFE, shown in Fig. 5b) as well as growth rate of
spheroids (indicated by the spheroid size) on day 4,
compared to WT cells (Fig. 5 C). CPEB2KD MCF7 cells
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Fig. 4 Translational regulation of p53 in CPEB2KO cells. a)qRT-PCR for p53 mRNA expression showing no difference between WT and CPEB2KO
cells. b Western Blots for p53 and (c) quantification of western blots showing p53 protein expression was significantly reduced (to 0.41) in
CPEB2KO cells. d, g p21 (downstream effector of p53) protein expression was significantly reduced (to 0.34) in CPEB2KO compared to WT cells.
Western blot presented in (d) and quantitation in (g). Data represent mean of 3 replicates ± SEM. (**) indicates p < 0.001, (***) p < 0.0001. e
Polysomal profiles of global protein translation in WT and CPEB2KO MCF10A cells showing no difference. f RT-PCR was performed to evaluate the
distribution across a sucrose density gradient of ACTB and p53 mRNAs, showing that p53 mRNA was significantly shifted toward light polysomes
in CPEB2KO cells

also displayed significant increase in spheroid formation
(morphology shown in Fig. 5d and SFE in Fig. 5e).
Wnt/β-Catenin signaling is a well-known pathway
used by cancer cells for multiple malignancy-associated
functions including SLC properties [39], as demonstrated in COX-2 over-expressing breast cancer cells [6].
CPEB2 was reported to bind β-Catenin mRNA to repress translation in mouse neuronal cells [40]. Therefore
we compared the levels of β-Catenin protein in WT and
CPEB2KO MCF10A cells, as well as changes in the expression of genes (AXIN2, AXIN1, CCND1, cMyc) downstream in the canonical Wnt/β-Catenin pathway. Western
blot for β-Catenin protein revealed an increase in CPEB2
KO compared to WT cells (Fig. 5g and h). This was associated with significant increases in CCND1 and AXIN1
mRNAs (Fig. 5f), suggesting that Wnt/β-Catenin pathway

may be involved in SLC stimulation noted earlier. We also
immuno-stained spheroids for certain SLC-associated
markers, as reported earlier [6]. CPEB2KD MCF7 cells
showed significantly increased incidence of cells expressing SOX2, NANOG and ALDH1, compared to control
mock-transfected MCF7 cells (Fig. 6).
CPEB2KO MCF10A cells reveal an upregulation of VEGF-D,
COX-2 and EP4

We reported that ectopic COX-2 over-expressing MCF7
cells displayed an upregulation of VEGF-A, VEGF-D and
EP4 receptor [6]. Furthermore two COX-2-upregulated
miRNAs miR-526b and miR-655, which target CPEB2,
when ectopically over-expressed in miRNA-low MCF7
cells led to an upregulation of EP4 and COX-2, indicating a positive feed-back loop for pathways in SLC
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Fig. 5 Increased spheroid formation by CPEB2-KO and CPEB2-KD cells. a Representative images of spheroids (Scale = 60 μm) and (b) spheroid
forming efficiency (SFE) of WT and CPEB2KO MCF10A cells grown on ultra-low attachment plates for 4 days. SFE is computed as the number of
spheroids (> 60 μm) divided by total number of cells plated. CPEB2KO cells showed 5.12-fold increase in SFE (p < 0.001). c Dot plot of spheroid
size (Mann-Whitney Test for statistical significance) showing increased average diameter (WT = 70.92 μm, CPEB2KO = 91.42 μm; p < 0.0005),
indicating enhanced spheroid growth rate. d Images of spheroids and (e) SFE in Mock and CBEB2-KD MCF7 cells, showing an increase in CPEB2KD cells. h Representative Western blot and (g) quantification (Mean of 3 ± SEM) of β- Catenin protein expression. f qRT-PCR (Mean of 3 ± SEM)
for downstream genes of β-Catenin pathway. β-Catenin was increased 1.29 fold (p = 0.048) in CPEB2KO cells, with increases in downstream target
genes CCND1 (3.49 fold, p = 0.039), and AXIN1 (1.298 fold, p = 0.034). No significant change was observed in AXIN2 (1.73 fold change, p = 0.10) or
Myc (0.76 fold change, p = 0.051)

sustenance [11, 12]. These findings prompted us measure VEGF, EP4 and COX-2 mRNAs in CPEB2KO
MCF10A cells. We found a significant upregulation of
VEGF-D, COX-2 and EP4 mRNAs (Additional file 3: Figure S3). Conversely, inhibition of COX-2 or EP4 activity
in MCF7-COX2 cells which was found to suppress SLC
activity [6] also upregulated CPEB2 (data not presented).
CPEB2KO MCF10A cells form tumors in immunecompromised mice

Using NOD/SCID/IL2Rϒ-null mice, we confirmed the findings that wildtype MCF10A cells, although immortalized, are
epithelial in nature and non-tumorigenic [31, 41]. Intravenous inoculation of WT cells resulted in no identifiable lung
colonization by gross or histological examination (H &E

staining) or staining for HLA at 8 weeks. However,
CPEB2KO cells formed micro-metastasis-like lesions in the
lungs identified with H&E staining and staining for HLA
(Fig. 7a), which could identify single cells, clusters and colonies. Quantitative data at 8 weeks are provided in Fig. 7b.
Furthermore, macroscopic tumours at the mammary sites
(illustrated in Fig. 7d) were noted after subcutaneous injection of the CPEB2KO cells in all mice at 9 out of 10 injection
sites, but none with wild-type cells, validated with immunostaining for HLA at 12 weeks (illustrated in Fig. 7c). At 12
weeks, some of the former mice (2 out of 5) displayed spontaneous metastases to the lungs, identified with the HLA
marker. Average incidence per lung sections was (400 μm)2
was: CPEB2KO-1: 15 +/− 2 single cells, 10+/− 2 Clusters,
and 4+/− 1 colonies; CPEBE2 KO-2: 12+/− 2 single cells, 8+/
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Fig. 6 SLC markers in Mock and CPEB2KD MCF7 spheroids. Immunofluorescence images for SLC markers (a) SOX2, (b) NANOG and (c) ALDH1 in
green, nuclei stained blue with DAPI in spheroids, (scale = 50 μm). Quantitative data for SLC markers, (d) for SOX2, (e) for NANOG and (f) ALDH1
showing an increase in markers bearing cells in CPEB2-KD spheroids compared to MCF7-Scramble spheroids. Data presented as mean of 3
replicates ± SEM (*) indicates p < 0.05

− 2 clusters and 3+/− 1 colonies. None of the mice injected
with WT cells displayed any lung metastasis.
CPEB2 isoforms a and B expression in human breast
cancer tissues

An examination of CPEB2 expression in TNBC was reported
be isoform-selective, having increased B/A ratio [29]. We examined the expression of CPEB2 isoforms A (indistinguishable from E, by the available probe) and B (indistinguishable
from D, by the available probe) in 105 breast cancer and 20
histologically confirmed non-tumour breast tissues (Fig. 8).
Compared to non-tumor breast tissues, cancerous tissues exhibited a lower expression of isoform A and a higher expression of isoform B, as indicated by ΔCT, lower values
indicating higher expression. The ratio of A/B isoforms (ratios of mean of ΔCT) was higher in non-tumor tissues (Fig.
8a), supporting the reports that A is the tumor-suppressor
isoform and B the tumor-promoter isoform [29, 30]. The information on ER, PR and HER2 status (n value) was available
in 98 out of 105 samples as follows: 19 HER2+, 64 HER2-,

75 ER+, 18 ER-, 64 PR+, 29 PR-, 11 ER/PR/HER+ and 10
ER/PR/HER2-. A comparison of CPEB2A and CPEB2B expression in different tumor subsets revealed no significant
difference in any subset in our samples (Fig. 8b).

Discussion
The roles of CPEB2 in human breast tumorigenesis have
so far remained a paradox, until isoform-specific roles
were identified [29, 30]. Selecting cells from TNBC cell
lines for anioikosis-resistance, these authors observed
that alternative splicing resulting in the loss of CPEB2A
with concomitant increase in CPEB2B was responsible
for their metastatic phenotype. CPEB2 was shown to
suppress the translation of two oncogenic transcription
factors, TWIST1 [27] - an EMT inducer, and HIF1α [24]
associated with many oncogenic functions [24, 25]. Deligio et al. [30] reported that anoikosis-resistance and metastasis phenotype of TNBC cell lines resulted from
CPEB2B isoform mediated translational activation of
HIF1α and TWIST1. They suggested that CPEB2B plays
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Fig. 7 Tumorigenicity of WT and CBEB2KO MCF10A cells in NOD/SCID/IL2Rγ null mice. a, b Intravenous injection of cells (5 × 105 cells per mouse,
n = 6 mice per cell line) resulted in lung metastasis of CPEB2KO but not WT cells. a Top panel: HLA stained (green) tumor cells (single cells,
clusters and colonies) noted in the lungs with CPEB2KO inocula. Nuclei stained blue with DAPI. Bottom panel: H&E stained lung showing a small
tumor-like lesion (pointed with arrow) with CPEB2KO inoculam. Scale = 50 μm (IF images) and 100 μm (H&E images). b Incidence of single tumor
cells, clusters (2–8 cells) and colonies (more than 8 cells) within lung sections immunostained with HLA antibody. Tumor cells were identified in
the lungs of all mice inoculated with CPEB2KO cells but none of the lungs in mice inoculated with WT cells. Data presented as mean of 5 images
per section, 3 non-serial sections per mouse ± SEM. c, d Subcutaneous inocula (5 × 105 cells per site, 2 inguinal mammary sites per mouse, mixed
with Matrigel, n = 5 mice in each group) of WT and CPEB2KO cells at the mammary sites of NOD/SCID/IL2Rγ-null mice. CPEB2KO cells formed
local tumours in all mice, some of which (2 out 5, 40%) spontaneously metastasized to the lung. No tumor resulted in any mouse from WT cells.
Tumour-forming efficiency was 90%, as calculated by number of sites showing local tumours (nine) divided by total number of injection sites
(ten). Each mouse showed one or two tumors: 4 with double and 1 with single tumor. d Representative images of mice and mammary fat pads
at 12 weeks. Arrow pointing to a tumor. c Representative images of tissues from sites inoculated with WT or CPEB2KO MCF10A cells,
immunostained with HLA antibody. Tumor cells (identified only with CPEB2KO cells) stained green, and nuclei stained blue with DAPI

an antagonistic role against CPEB2A by alleviating the
translational inhibition of HIF1α and TWIST1 imparted
by CPEB2A.
In the present study, by depleting the entire CPEB2 gene,
we demonstrated a robust role of CPEB2 in suppressing a
variety of oncogenic functions in both MCF10A and MCF7
cell lines, evidently due to the CPEB2A isoform, prevalent in
both cell lines. Reportedly, no alternative splicing of CPEB2
or presence of isoform B was detectable MCF10A cell line
[29]. In both cell lines, we found that CPEB2 downregulation
promoted EMT, proliferation, migratory and invasive

functions, as well as SLC phenotype measured with
spheroid-forming ability. The spheroids formed by
CPEB2KO MCF10A cells exhibited a higher growth rate, indicating a faster self-renewal of the SLC population. Increased β-Catenin protein noted in CPEB2KO cells may be
responsible for a higher self-renewal capacity of stem-like
cells or increased proliferative ability of non-stem cells. For
example, increased β-Catenin signaling can lead to increased
expression of CCND1, a nuclear protein, that forms a complex with CDK4 and CDK6 leading to progression of cells
from G1 into S-phase [42].
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Fig. 8 Expression of CPEB2 isoforms A and B in human breast cancer tissues and non- tumor breast tissues. Expression of CPEB2 isoforms A
(measured with an A/E probe) and B (measured with a B/D probe) mRNAs were analyzed by qPCR in105 breast cancer tissues (6 samples failing
to amplify expression of GAPDH or CPEB2A were removed from the study) and in 20 control (histologically tumor-free) breast tissues. a The
control non-tumor tissues expressed relatively higher expression of isoform A, and lower expression of isoform B than tumor tissues, when
normalized for GAPDH. They are plotted as A/B ratios of the delta Ct ± SEM. * indicates p < 0.05. b We measured CPEB2A (with an A/E probe) and
CPEB2B (with a B/D probe) mRNA in various tumor subsets, ER+, ER-, PR+, PR-, HER2+, HER2-, ER/PR/HER2- normalized to GAPDH. Data presented
as delta Ct ± SEM. No significant difference in the expression of A vs B was noted in any subset. c A schema for molecular partners in CPEB2
regulation and action in breast cancer. COX-2 via EP4 activation upregulates two oncogenic miRNAs miR-526b and miR-655, both of which target
CPEB2. Tumor suppressor functions of CPEB2 (resulting from the isoform A) are mediated by multiple partners: translational regulation of p53,
HIF-1α and Twist-1 mRNAs. In addition CPEB2 appears to suppress COX-2/EP4 expression by hitherto unknown mechanisms

During EMT, polar epithelial cells assume an elongated nonpolar mesenchymal morphology, associated
with an acquisition of mesenchymal cell markers, increased migratory ability, cell survival, and invasiveness
[43]. E-Cadherin, an epithelial cell junction-associated
protein mediates cell-cell adhesions, contact inhibition
and control of cell proliferation [34]. It is lost during
EMT [35], as shown with CPEB2KO or KD cells. However, EMT also requires “Cadherin switching” in which
expression of E-Cadherin is exchanged for other cadherins, such as N-Cadherin [44, 45]. Ectopic overexpression of N-Cadherin in MCF7 cells stimulated migration and invasiveness through upregulation of MMP9 and metastasis [46]. Here, in CPEB2KO MCF10A cells,
a switch from E-Cadherin to N-Cadherin was clearly evident. Increased MMP-9 activity shown with gelatin
zymography explained their increased invasive capacity.
While transcriptional regulation of N-Cadherin during
cadherin switching is unknown, Twist1 can modulate NCadherin expression by binding to the E-box on CDH2
(N-Cadherin) [45, 47].

Numerous transcription factors may have contributed
to the EMT phenotype in CPEB2KO cells. TWIST1 can
mediate EMT [48], and also inhibit apoptosis through evasion of p53-induced cell death [49]. CPEB2 mediated
translational repression of TWIST1, a function ascribed to
the A isoform [30] could be a mechanism by which EMT
is suppressed. In support, in CPEB2KO cells exhibited no
change in TWIST1 mRNA expression, suggesting posttranscriptional regulation by CPEB2. An increase in
SNAI1 and ZEB1, observed in CPEB2KO cells, could additionally contribute to EMT. Both molecules are known to
suppress transcription of E-Cadherin and play important
roles in invasion and metastasis [50, 51].
P53 is a master tumour-suppressor, responsible for suppressing EMT, migration, and invasion through transcriptional regulation of many other molecules [52]. Here, we
show for the first time that CPEB2 is a novel translational
regulator of p53, as was reported for CPEB1 [38]. Polysome profiling confirmed that a reduction in p53 protein
in CBEB2KO cells is due to reduced p53 mRNA translation resulting from shortened Poly A tail, rather than an
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indirect mechanism by binding to another target molecule. Additionally, another tumor suppressor protein
p21, a downstream partner of p53 was also reduced in
CPEB2 KO cells.
We have shown that ectopic COX-2 overexpression
in MCF7 cells promoted SLC phenotype associated
with increased expression of EP4 receptor, Notch
and Wnt [6]. Wnt pathway protein β-Catenin and
the downstream Wnt pathway genes CCND1, AXIN1
and AXIN2 were all significantly upregulated in
MCF7-COX2 spheroids [6]. In the present study
CPEB2KO cells exhibited an upregulation of βCatenin protein, AXIN1 gene, and interestingly also
COX-2 and EP4 genes linking with SLC phenotype
[6]. It is likely that an upregulation of COX-2/EP4
provided a positive feed-back loop for SLC sustenance in CPEB2KO cells, as shown for miR-526-B
and miR-655 overexpressing cells [11, 12]. Conversely, treating MCF7-COX2 cells with either a
COX-2 inhibitor celecoxib or with an EP4 antagonist
ONO-AE3–208 significantly up-regulated CPEB2 in
these cells (data not presented), concomitant with a
marked drop in their spheroid-forming capacity [6].
The molecular mechanisms underlying this CPEB2COX2/EP4 regulatory loop remains to be investigated. One possible pathway is binding of CPEB2 to
HIF-1α [24], a known upregulator of COX-2. Furthermore, increased β-Catenin protein noted in
CPEB2KO cells can stabilize COX2 mRNA by interacting with AU-rich elements of 3′-UTR [53]. Collectively, the SLC stimulation in CPEB2KO MCF10A
cells could be due to an upregulation of COX2/EP4,
and Wnt pathway genes.
Finally an examination of breast cancer and nontumor breast tissues revealed a lower expression CPEB2
isoform A and higher expression of isoform B in cancerous tissues. This difference was more evident by measuring the ratios of A: B isoforms, presented in Fig. 8a.
These results are in concordance with reported tumorsuppressor vs tumor-promoter functions of A and B isoforms [30]. However our probes could not demonstrate
a preferential expression of A (A/E) or B (B/D) isoform
in any of the tumor subsets based on the information on
their ER, PR or HER2 status. Since these samples contained variable proportion of stromal and immune cells,
it is possible that they may have masked the differences.
In summary, we demonstrate here that CPEB2, presumably the isoform A, plays a significant role in suppressing tumorigenesis in mammary epithelial cells by
repressing EMT, migration, invasion, proliferation and
SLC phenotype, possibly through multiple targets, one
of them identified here as p53. Figure 8c presents a
schema for the proposed mechanisms in tumor suppressor functions of CPEBE2.
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Conclusions
Present study, utilizing in vitro and in vivo functional assays in CPEB2-depleted mammary epithelial cells as well
as human breast-derived non-tumor and cancerous tissues, demonstrates that CPEB2, presumably the isoform
A, plays a key role in suppressing tumorigenesis in
mammary epithelial cells. The underlying mechanisms
involved suppression of EMT, migration, invasion, proliferation and SLC phenotype, via a newly-identified translational target p53.
Additional files
Additional file 1: Figure S1. EMT marker proteins identified in MOCK
and CPEB2KD MCF7 cells. Top panel: (A) and (B). Immunofluorescence
Images for E-Cadherin and Twist 1 (stained green), nuclei stained blue
with DAPI. CPEBKD cells show decreased E-Cadherin on cell membranes,
and increased Twist 1 in cytoplasm. Bottom panel: Left, (C) and (D):
Quantification of fluorescence (normalized to 1 for control mock cells
showing significant reduction of E-Cadherin and increase in Twist 1 in KD
cells (p < 0.05). Right, (E) Western blots showing decreased E-Cadherin
and increased Twist 1, and a very minor increase (not significant) in
Vimentin. (JPG 173 kb)
Additional file 2: Figure S2. Migration, invasion and proliferation in
MCF7 cells after CPEB2KD. (A) Migration and (B) invasion measured in
transwells respectively at 24 and 48 h reveal significant increases in
CPEB2KD cells (p < 0.05). (C) Proliferation measured with 24 h BrdU
uptake showed a minor increase, not significant (p = 0.06). Data represent
means of 3 replicates (±SEM). (JPG 78 kb)
Additional file 3: Figure S3. VEGF-D, COX-2 (PTGS2) and EP4 (PTGER4)
expression in MCF10A cells. Expression of mRNA (qRT-PCR; Mean ± SEM)
for VEGF, COX-2 and EP4 in WT and CPEB2KO cells (n = 3). No change
was seen in the expression of VEGFB or VEGF-C, however a 4.68-fold upregulation of VEGF-D was seen in the CPEB2KO cells compared to WT
cells (p = 0.0020). COX-2 mRNA expression increased 4.31-fold (p = 0.0024)
and EP4 mRNA expression increased 3.45-fold (p = 0.011) compared to
WT cells. (*) indicates p < 0.05. (**) indicates p < 0.01. (JPG 58 kb)
Additional file 4: Table S1. Differential gene and microRNA microarrays
conducted with MCF7 and MCF7-COX-2 cells identified two COX-2 upregulated miRNAs miR526b and miR655. They collectively target 13 COX2 downregulated genes, of which CPEB2 appeared as the single common
target. (DOCX 17 kb)
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